Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Reporting the details of consent procedures in clinical trials.

Dal Ré R, Solberg B, Fuhr U, Eriksson S.

J Clin Epidemiol. 2019 Sep 19. pii: S0895-4356(19)30546-3. doi: 10.1016/j.jclinepi.2019.09.014. [Epub ahead of print] No abstract available.

PMID:
31542507
2.

A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation.

Scherf-Clavel O, Kinzig M, Stoffel MS, Fuhr U, Sörgel F.

J Pharm Biomed Anal. 2019 Oct 25;175:112754. doi: 10.1016/j.jpba.2019.07.002. Epub 2019 Jul 3.

PMID:
31336285
3.

Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies.

Scherf-Clavel O, Kinzig M, Stoffel MS, Fuhr U, Sörgel F.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121718. doi: 10.1016/j.jchromb.2019.121718. Epub 2019 Jul 16.

PMID:
31330406
4.

Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey.

Karas Kuželički N, Prodan Žitnik I, Gurwitz D, Llerena A, Cascorbi I, Siest S, Simmaco M, Ansari M, Pazzagli M, Di Resta C, Brandslund I, Schwab M, Vermeersch P, Lunshof JE, Dedoussis G, Flordellis CS, Fuhr U, Stingl JC, van Schaik RH, Manolopoulos VG, Marc J; Pharmacogenomics Education Working Group (PGxEWG); European Society of Pharmacogenomics and Personalized Therapy (ESPT).

Pharmacogenomics. 2019 Jun;20(9):643-657. doi: 10.2217/pgs-2019-0009.

5.

A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin.

Trueck C, Hsin CH, Scherf-Clavel O, Schaeffeler E, Lenssen R, Gazzaz M, Gersie M, Taubert M, Quasdorff M, Schwab M, Kinzig M, Sörgel F, Stoffel MS, Fuhr U.

Clin Pharmacol Ther. 2019 Jun 27. doi: 10.1002/cpt.1564. [Epub ahead of print]

PMID:
31247117
6.

A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers.

Liu R, Li X, Wei J, Liu S, Chang Y, Zhang J, Zhang J, Zhang X, Fuhr U, Taubert M, Tian X.

Front Pharmacol. 2019 May 14;10:518. doi: 10.3389/fphar.2019.00518. eCollection 2019.

7.

A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.

Ullah S, Matzneller P, Zeitlinger M, Fuhr U, Taubert M.

Naunyn Schmiedebergs Arch Pharmacol. 2019 Sep;392(9):1097-1106. doi: 10.1007/s00210-019-01647-w. Epub 2019 May 6.

PMID:
31062064
8.

Low risk pragmatic trials do not always require participants' informed consent.

Dal-Ré R, Avendaño-Solà C, Bloechl-Daum B, de Boer A, Eriksson S, Fuhr U, Holm S, James SK, Mentz RJ, Perucca E, Rosendaal FR, Treweek S.

BMJ. 2019 Mar 27;364:l1092. doi: 10.1136/bmj.l1092. No abstract available. Erratum in: BMJ. 2019 Apr 1;365:l1518.

PMID:
30917969
9.

Using a three-compartment model improves the estimation of iohexol clearance to assess glomerular filtration rate.

Taubert M, Ebert N, Martus P, van der Giet M, Fuhr U, Schaeffner E.

Sci Rep. 2018 Dec 7;8(1):17723. doi: 10.1038/s41598-018-35989-x.

10.

Response to "Impact of Acute Alcohol Exposure on P-Glycoprotein Function at the Blood-Brain Barrier Assessed Using 11 C-Metoclopramide PET Imaging".

Hsin CH, Fuhr U, Trueck C.

Clin Pharmacol Ther. 2019 Apr;105(4):814. doi: 10.1002/cpt.1265. Epub 2018 Dec 4. No abstract available.

PMID:
30515759
11.

Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose.

Li X, Zoller M, Fuhr U, Huseyn-Zada M, Maier B, Vogeser M, Zander J, Taubert M.

J Antimicrob Chemother. 2019 Mar 1;74(3):682-690. doi: 10.1093/jac/dky485.

PMID:
30500905
12.

Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited.

Fuhr U, Hsin CH, Li X, Jabrane W, Sörgel F.

Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:507-536. doi: 10.1146/annurev-pharmtox-010818-021909. Epub 2018 Aug 29.

PMID:
30156973
13.

Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.

Arshad U, Taubert M, Kurlbaum M, Frechen S, Herterich S, Megerle F, Hamacher S, Fassnacht M, Fuhr U, Kroiss M.

Eur J Endocrinol. 2018 Oct 16;179(5):287-297. doi: 10.1530/EJE-18-0342.

PMID:
30087117
14.

Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects.

Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F.

Pharmacology. 2018;102(3-4):133-137. doi: 10.1159/000489999. Epub 2018 Jul 6.

PMID:
29982257
15.

Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?

Gazzaz M, Kinzig M, Schaeffeler E, Jübner M, Hsin CH, Li X, Taubert M, Trueck C, Iltgen-Breburda J, Kraus D, Queckenberg C, Stoffel M, Schwab M, Sörgel F, Fuhr U.

Clin Pharmacol Ther. 2018 Dec;104(6):1249-1259. doi: 10.1002/cpt.1083. Epub 2018 May 10.

PMID:
29633238
16.

Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections.

Taubert M, Lückermann M, Vente A, Dalhoff A, Fuhr U.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02328-17. doi: 10.1128/AAC.02328-17. Print 2018 Apr.

17.

Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples.

Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F.

Pharmacology. 2018;101(1-2):29-34. doi: 10.1159/000480091. Epub 2017 Sep 21.

18.

Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.

Taubert M, Chiesa J, Lückermann M, Fischer C, Dalhoff A, Fuhr U.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01122-17. doi: 10.1128/AAC.01122-17. Print 2017 Oct.

19.

Pharmacokinetic Phenotyping to Predict Drug-Drug Interactions: Time to Divorce the Hybrid Concept of Simultaneous Mechanistic-Based and Exposure-Based Assessment.

Fuhr U.

Clin Pharmacol Ther. 2018 Jan;103(1):42. doi: 10.1002/cpt.772. Epub 2017 Jul 29. No abstract available.

PMID:
28755427
20.

Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome.

Dahlinger D, Aslan S, Pietsch M, Frechen S, Fuhr U.

Ther Adv Urol. 2017 Jun 21;9(7):163-177. doi: 10.1177/1756287217708951. eCollection 2017 Jul.

21.

Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens.

Taubert M, Zander J, Frechen S, Scharf C, Frey L, Vogeser M, Fuhr U, Zoller M.

J Antimicrob Chemother. 2017 Aug 1;72(8):2304-2310. doi: 10.1093/jac/dkx149.

PMID:
28541510
22.

Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.

Taubert M, Zoller M, Maier B, Frechen S, Scharf C, Holdt LM, Frey L, Vogeser M, Fuhr U, Zander J.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5254-61. doi: 10.1128/AAC.00356-16. Print 2016 Sep.

23.

Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples.

Sigaroudi A, Stelzer C, Braun T, Frechen S, Hüttner S, Schröter M, Kinzig M, Fuhr U, Holzgrabe U, Sörgel F.

Pharmacology. 2016;98(1-2):70-2. doi: 10.1159/000445720. Epub 2016 Apr 23.

PMID:
27104875
24.

Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhaler.

Frechen S, Suleiman AA, Mohammad Nejad Sigaroudi A, Wachall B, Fuhr U.

Drug Metab Pharmacokinet. 2015 Dec;30(6):391-9. doi: 10.1016/j.dmpk.2015.08.002. Epub 2015 Aug 28.

PMID:
26615448
25.

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.

Schöttle J, Chatterjee S, Volz C, Siobal M, Florin A, Rokitta D, Hinze Y, Dietlein F, Plenker D, König K, Albus K, Heuckmann JM, Rauh D, Franz T, Neumaier B, Fuhr U, Heukamp LC, Ullrich RT.

Oncotarget. 2015 Nov 17;6(36):38458-68. doi: 10.18632/oncotarget.6276.

26.

Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition.

Dahlinger D, Duechting S, Nuecken D, Sydow K, Fuhr U, Frechen S.

J Pharmacol Toxicol Methods. 2016 Jan-Feb;77:66-75. doi: 10.1016/j.vascn.2015.10.003. Epub 2015 Oct 31.

PMID:
26528794
27.

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.

Suleiman AA, Frechen S, Scheffler M, Zander T, Nogova L, Kocher M, Jaehde U, Wolf J, Fuhr U.

AAPS J. 2015 Nov;17(6):1483-91. doi: 10.1208/s12248-015-9815-8. Epub 2015 Aug 19.

28.

Adverse events during placebo vs. no drug administration--results of a randomised interventional trial in 160 volunteers.

Erbguth F, Hamacher-Erbguth A, Fuhr U, Sörgel F.

Eur J Clin Pharmacol. 2015 Nov;71(11):1403-5. doi: 10.1007/s00228-015-1900-5. Epub 2015 Aug 14. No abstract available.

PMID:
26268442
29.

Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.

Queckenberg C, Erlinghagen V, Baken BC, Van Os SH, Wargenau M, Kubeš V, Peroutka R, Novotný V, Fuhr U.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1081-91. doi: 10.1007/s00280-015-2840-6. Epub 2015 Aug 5.

PMID:
26242222
30.

Channeling the flood of meta-analyses.

Fuhr U, Hellmich M.

Eur J Clin Pharmacol. 2015 Jun;71(6):645-647. doi: 10.1007/s00228-015-1838-7. Epub 2015 Apr 25. No abstract available.

PMID:
25907008
31.

Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.

Suleiman AA, Frechen S, Scheffler M, Zander T, Kahraman D, Kobe C, Wolf J, Nogova L, Fuhr U.

J Thorac Oncol. 2015 Jan;10(1):84-92. doi: 10.1097/JTO.0000000000000330.

32.

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.

Loibl S, Rokitta D, Conrad B, Harbeck N, Wüllner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Mehta K, Fuhr U, von Minckwitz G.

Breast Care (Basel). 2014 Jul;9(3):169-74. doi: 10.1159/000363430.

33.

Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam.

Tomalik-Scharte D, Suleiman AA, Frechen S, Kraus D, Kerkweg U, Rokitta D, Di Gion P, Queckenberg C, Fuhr U.

J Clin Pharmacol. 2014 Oct;54(10):1162-9. doi: 10.1002/jcph.318. Epub 2014 May 5.

PMID:
24782075
34.

A novel toxicokinetic modeling of cypermethrin and permethrin and their metabolites in humans for dose reconstruction from biomarker data.

Côté J, Bonvalot Y, Carrier G, Lapointe C, Fuhr U, Tomalik-Scharte D, Wachall B, Bouchard M.

PLoS One. 2014 Feb 26;9(2):e88517. doi: 10.1371/journal.pone.0088517. eCollection 2014.

35.

Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide.

Cawello W, Fuhr U, Hering U, Maatouk H, Halabi A.

Clin Pharmacokinet. 2013 Oct;52(10):897-906. doi: 10.1007/s40262-013-0080-7.

PMID:
23737404
36.

The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro.

Rokitta D, Pfeiffer K, Streich C, Gerwin H, Fuhr U.

Toxicol Mech Methods. 2013 Oct;23(8):576-83. doi: 10.3109/15376516.2013.806622. Epub 2013 Oct 7.

PMID:
23682612
37.

Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.

Krause P, Fuhr U, Schnitker J, Albrecht U, Stein R, Rubenwolf P.

J Urol. 2013 Nov;190(5):1791-7. doi: 10.1016/j.juro.2013.05.011. Epub 2013 May 10.

PMID:
23669567
38.

A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Frechen S, Junge L, Saari TI, Suleiman AA, Rokitta D, Neuvonen PJ, Olkkola KT, Fuhr U.

Clin Pharmacokinet. 2013 Sep;52(9):763-81. doi: 10.1007/s40262-013-0070-9.

PMID:
23653047
39.

Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.

Abduljalil K, Lazar S, Natanzon M, Wu W, Zadoyan G, Steffens B, Kohl V, Mörike K, Tomalik-Scharte D, Stingl J, Schwab M, Harenberg J, Gleiter C, Fuhr U.

Clin Pharmacokinet. 2013 May;52(5):359-71. doi: 10.1007/s40262-013-0043-z.

PMID:
23519598
40.

Modeling NSCLC progression: recent advances and opportunities available.

Suleiman AA, Nogova L, Fuhr U.

AAPS J. 2013 Apr;15(2):542-50. doi: 10.1208/s12248-013-9461-y. Epub 2013 Feb 13.

41.

Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers.

Doroshyenko O, Rokitta D, Zadoyan G, Klement S, Schläfke S, Dienel A, Gramatté T, Lück H, Fuhr U.

Drug Metab Dispos. 2013 May;41(5):987-93. doi: 10.1124/dmd.112.050203. Epub 2013 Feb 11.

PMID:
23401474
42.

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.

Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.

Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.

PMID:
23314734
43.

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler.

Breuer C, Wachall B, Gerbeth K, Abdel-Tawab M, Fuhr U.

Eur J Clin Pharmacol. 2013 Jun;69(6):1303-10. doi: 10.1007/s00228-012-1465-5. Epub 2013 Jan 5.

44.

The role of human cytochrome P450 enzymes in metabolism of acrylamide in vitro.

Kraus D, Rokitta D, Fuhr U, Tomalik-Scharte D.

Toxicol Mech Methods. 2013 Jun;23(5):346-51. doi: 10.3109/15376516.2012.759307. Epub 2013 Jan 28.

PMID:
23256458
45.

Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps.

Watzek N, Scherbl D, Feld J, Berger F, Doroshyenko O, Fuhr U, Tomalik-Scharte D, Baum M, Eisenbrand G, Richling E.

Mol Nutr Food Res. 2012 Dec;56(12):1825-37. doi: 10.1002/mnfr.201200323. Epub 2012 Oct 27.

PMID:
23109489
46.

Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker.

Kanefendt F, Lindauer A, Mross K, Fuhr U, Jaehde U.

J Pharm Biomed Anal. 2012 Nov;70:485-91. doi: 10.1016/j.jpba.2012.06.039. Epub 2012 Jul 4.

PMID:
22819208
47.

Study on the dosing accuracy of commonly used disposable insulin pens.

Krzywon M, van der Burg T, Fuhr U, Schubert-Zsilavecz M, Abdel-Tawab M.

Diabetes Technol Ther. 2012 Sep;14(9):804-9. doi: 10.1089/dia.2011.0298. Epub 2012 Jun 13.

48.

Phenotyping studies to assess the effects of phytopharmaceuticals on in vivo activity of main human cytochrome p450 enzymes.

Zadoyan G, Fuhr U.

Planta Med. 2012 Sep;78(13):1428-57. doi: 10.1055/s-0031-1298536. Epub 2012 May 15. Review.

49.

Phenotyping the activity of drug metabolizing enzymes using limited sampling strategies: perturbations and bias.

Fuhr U.

Int J Clin Pharmacol Ther. 2012 Jul;50(7):476-7. doi: 10.5414/CP201701A. No abstract available.

PMID:
22541752
50.

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

Vehreschild JJ, Müller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, Kreuzer KA, Hallek M, Kohl V.

Eur J Clin Pharmacol. 2012 Jun;68(6):987-95. doi: 10.1007/s00228-012-1212-y.

PMID:
22286158

Supplemental Content

Support Center